Rethinking thalidomide.
出版信息
Environ Health Perspect. 1995 Feb;103(2):132.
Abstract
摘要
相似文献
1
Rethinking thalidomide.重新审视沙利度胺。
Environ Health Perspect. 1995 Feb;103(2):132.
2
Scientists take aim at angiogenesis to treat degenerative eye diseases.科学家将目标对准血管生成以治疗退行性眼病。
JAMA. 2004 Mar 17;291(11):1309-10. doi: 10.1001/jama.291.11.1309.
3
Technology evaluation: pegaptanib, Eyetech/Pfizer.技术评估：派加他尼，Eyetech/辉瑞公司
Curr Opin Mol Ther. 2003 Dec;5(6):673-9.
4
Current and emerging therapies for ocular neovascularisation.当前和新兴的眼部新生血管治疗方法。
Adv Exp Med Biol. 2014;801:797-804. doi: 10.1007/978-1-4614-3209-8_100.
5
Lipid metabolites in the pathogenesis and treatment of neovascular eye disease.脂质代谢物在新生血管性眼病发病机制和治疗中的作用。
Br J Ophthalmol. 2011 Nov;95(11):1496-501. doi: 10.1136/bjo.2010.194241. Epub 2011 Mar 18.
6
[Eye and pathologic angiogenesis].[眼睛与病理性血管生成]
Fukuoka Igaku Zasshi. 2000 Nov;91(11):277-83.
7
[Using thalidomide against pathological neovascularization].
Harefuah. 2003 Mar;142(3):212-6, 237.
8
Lowering lipids in eye disease.降低眼部疾病中的脂质水平。
Hosp Med. 2002 Dec;63(12):753.
9
Inhibiting angiogenesis in retinoblastoma.抑制视网膜母细胞瘤中的血管生成。
Ophthalmic Res. 2007;39(4):188-90. doi: 10.1159/000103578. Epub 2007 Jun 6.
10
[VEGF, anti-vEGF and diseases].[血管内皮生长因子、抗血管内皮生长因子与疾病]
Bull Acad Natl Med. 2008 Feb;192(2):289-300; discussion 300-2.
引用本文的文献
1
Thalidomide and its analogues: A review of the potential for immunomodulation of fibrosis diseases and opthalmopathy.沙利度胺及其类似物：纤维化疾病和眼病免疫调节潜力综述
Exp Ther Med. 2017 Dec;14(6):5251-5257. doi: 10.3892/etm.2017.5209. Epub 2017 Sep 27.
Zotero 插件